Latest Headlines

Latest Headlines

Spectrum nabs Allos buyout as bladder cancer drug fails PhIII

Spectrum Pharmaceuticals ($SPPI) put on the best face possible on the news that its bladder cancer drug apaziquone failed two late stage studies.

AMAG Pharma shareholders shoot down Allos buyout

After many criticisms of its plans, AMAG Pharmaceuticals ($AMAG) failed to get shareholder support today in their vote on the company's proposed buyout of Allos Therapeutics in a deal valued at

AMAG investor out to derail Allos merger with buyout offer

A few days ago AMAG Pharmaceuticals raised eyebrows with its proposed merger with Allos Therapeutics. The two companies didn't have much in common, aside from disappointing sales of two very

AMAG and Allos to merge, readying the budget axe

AMAG Pharmaceuticals ($AMAG) and Allos Therapeutics ($ALTH) struck a deal to merge in an all-stock transaction valued at $686 million. And the two developers have already identified $55 million to

Allos inks $360M Folotyn pact as cancer drug sales disappoint

After disappointing analysts with its sales numbers for Folotyn, Allos Therapeutics ($ALTH) turned around and announced an ex-North American licensing pact for the drug which will deliver $50 million

Allos lays off 13 percent of staff

While sales reps have been the target of many rounds of layoffs recently, Allos Therapeutics has taken a different approach with its announced layoffs. The Westminster, CO-based biotech is laying off

FDA approves Allos' cancer drug

Allos Therapeutics' shares were up 8 percent on the news that the FDA had approved Folotyn for use as a single agent for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It's

Allos shares plunge on blood cancer trial results

Slightly more than one out of every four patients taking an experimental blood cancer drug--pralatrexate--developed by Allos Therapeutics experienced a complete or partial response in a pivotal Phase

ALSO NOTED: Allos gains orphan status for cancer therapy; NICE recommends against Velcade; and much more...

> Allos Therapeutics has gained orphan drug status for an experimental cancer therapy. Report > The U.K.'s drug watchdog, the National Institute for Health and Clinical Excellence, has